Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Two-part Trial to Assess the Mass-balance Recovery, Metabolite Profile, Metabolite Identification and Absolute Bioavailability of [14C] Ontunisertib in Healthy Male Participants

NCT07672574 is registered in ClinicalTrials.gov with Agomab Spain S.L.U. as lead sponsor.

NCT NCT07672574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07672574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Two-part Trial to Assess the Mass-balance Recovery, Metabolite Profile, Metabolite Identification and Absolute Bioavailability of [14C] Ontunisertib in Healthy Male Participants
Lead sponsor
Agomab Spain S.L.U.
Phase
Phase 1
Overall status
Recruiting
Start date
September 9, 2026
Completion date
September 26, 2026
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibrostenotic crohn's disease